Synageva BioPharma (GEVA)

[surf1944]

Trimeris Appoints Martin A. Mattingly as Chief Executive Officer
Thursday November 15, 9:00 am ET

MORRISVILLE, N.C.--(BUSINESS WIRE)--Trimeris, Inc. (NASDAQ:TRMS - News) today announced the appointment of Martin A. Mattingly, Pharm.D. as Chief Executive Officer, effective immediately. Dr. Mattingly will also join the Company's board of directors.

“The Trimeris Board is extremely excited by Martin’s decision to join the Company. Martin’s hands-on experience in commercializing HIV products in crowded markets and in maximizing the value of these products as they mature is an ideal fit for Trimeris. During his tenure at Agouron and Pfizer, Martin was actively involved in both the successful launch of VIRACEPT® (nelfinavir mesylate) and its life-cycle management as numerous competitors entered the market,” said Julian Baker, member of the Company’s board of directors.

Dr. Mattingly brings significant experience as a biotechnology and pharmaceutical executive. He was most recently President and Chief Executive Officer of Ambrx Pharmaceuticals. Prior to that, Dr. Mattingly served as Executive Vice President and Chief Operating Officer at CancerVax. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals and Pfizer. These assignments included General Manager for the Agouron HIV division; Vice President, Product Development Group; and Vice President, Global Marketing Planning. From 1983 to 1996, Dr. Mattingly held various positions in oncology marketing and sales management at Eli Lilly and Company. He holds a Doctor of Pharmacy degree from the University of Kentucky.

“I am very pleased and excited to be a member of the Trimeris team,” said Dr. Mattingly. “The Company has significant assets, including the breakthrough HIV/AIDS treatment FUZEON. I look forward to working with the management team to maximize shareholder value".

also 10-Q out

http://biz.yahoo.com/e/071109/trms10-q.html